Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is…

Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of…

Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is…

As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups…

One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how…

Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among…

In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is…

David H. Crean, Managing General Partner for Coast BioVentures, updates and highlights the latest trends in the cell and gene therapy market for deal…

Amr Seif introduces the evolution in Astellas' MEA strategy; the adoption of innovative access models to ensure that the companies' therapies are…

Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need…

Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow…

Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those…